Masafumi Ikeda

33.8k total citations · 6 hit papers
485 papers, 12.9k citations indexed

About

Masafumi Ikeda is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Masafumi Ikeda has authored 485 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 288 papers in Oncology, 184 papers in Hepatology and 142 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Masafumi Ikeda's work include Hepatocellular Carcinoma Treatment and Prognosis (170 papers), Pancreatic and Hepatic Oncology Research (164 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (109 papers). Masafumi Ikeda is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (170 papers), Pancreatic and Hepatic Oncology Research (164 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (109 papers). Masafumi Ikeda collaborates with scholars based in Japan, United States and South Korea. Masafumi Ikeda's co-authors include Takuji Okusaka, Masatoshi Kudo, Chigusa Morizane, Hideki Ueno, Junji Furuse, Makoto Ueno, Hiroshi Ishii, Richard S. Finn, Andrew X. Zhu and Shuichi Mitsunaga and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Masafumi Ikeda

464 papers receiving 12.7k citations

Hit Papers

Updated efficacy and safe... 2014 2026 2018 2022 2021 2020 2014 2019 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
    2021 891 citations Ann‐Lii Cheng, Shukui Qin et al. profile →
  2. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
    2020 850 citations Richard S. Finn, Masafumi Ikeda et al. Journal of Clinical Oncology profile →
  3. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
    2014 456 citations Masatoshi Kudo, Takuji Okusaka et al. profile →
  4. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
    2019 247 citations Makoto Ueno, Masafumi Ikeda et al. profile →
  5. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    2021 229 citations Richard S. Finn, Masafumi Ikeda et al. Journal of Clinical Oncology profile →
  6. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
    2020 194 citations Masatoshi Kudo, Masafumi Ikeda et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masafumi Ikeda Japan 55 6.1k 5.7k 3.2k 3.0k 2.8k 485 12.9k
Tim Meyer United Kingdom 55 4.9k 0.8× 6.7k 1.2× 2.2k 0.7× 4.2k 1.4× 2.2k 0.8× 237 13.8k
Robin Kate Kelley United States 51 6.1k 1.0× 6.1k 1.1× 4.4k 1.4× 3.0k 1.0× 3.4k 1.2× 215 15.4k
Takuji Okusaka Japan 65 10.7k 1.8× 5.4k 0.9× 6.3k 1.9× 5.3k 1.8× 4.7k 1.7× 534 19.6k
Daniel H. Palmer United Kingdom 39 5.3k 0.9× 3.3k 0.6× 4.7k 1.4× 2.4k 0.8× 3.0k 1.1× 219 11.7k
Valérie Boige France 63 9.5k 1.6× 3.9k 0.7× 5.7k 1.7× 2.1k 0.7× 6.2k 2.2× 287 17.6k
Junji Furuse Japan 54 6.6k 1.1× 3.9k 0.7× 4.7k 1.4× 2.9k 1.0× 3.7k 1.3× 421 12.7k
Ho Yeong Lim South Korea 58 6.6k 1.1× 4.4k 0.8× 3.6k 1.1× 2.0k 0.7× 5.7k 2.0× 369 15.0k
Shukui Qin China 51 5.2k 0.9× 5.3k 0.9× 1.8k 0.6× 1.9k 0.7× 3.8k 1.3× 337 12.0k
Sasan Roayaie United States 40 2.7k 0.4× 6.4k 1.1× 3.2k 1.0× 3.6k 1.2× 2.1k 0.8× 88 12.0k
Ronnie T. P. Poon Hong Kong 54 3.5k 0.6× 4.5k 0.8× 3.0k 0.9× 2.3k 0.8× 1.7k 0.6× 137 10.2k

Countries citing papers authored by Masafumi Ikeda

Since Specialization
Citations

This map shows the geographic impact of Masafumi Ikeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masafumi Ikeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masafumi Ikeda more than expected).

Fields of papers citing papers by Masafumi Ikeda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masafumi Ikeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masafumi Ikeda. The network helps show where Masafumi Ikeda may publish in the future.

Co-authorship network of co-authors of Masafumi Ikeda

This figure shows the co-authorship network connecting the top 25 collaborators of Masafumi Ikeda. A scholar is included among the top collaborators of Masafumi Ikeda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masafumi Ikeda. Masafumi Ikeda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nakamura, Yoshiaki, Bennett Adam Caughey, Binbin Zheng-Lin, et al.. (2025). Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer. JCO Precision Oncology. 9(9). e2400718–e2400718. 1 indexed citations
2.
3.
Ikeda, Masafumi, Susumu Hijioka, Tetsuhide Ito, et al.. (2024). Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors. Japanese Journal of Clinical Oncology. 54(8). 880–886.
4.
Nakachi, Kohei, Masafumi Ikeda, Masaru Konishi, et al.. (2024). Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202/ASCOT.. Journal of Clinical Oncology. 42(16_suppl). 4119–4119. 1 indexed citations
5.
He, Aiwu Ruth, Do‐Youn Oh, Teresa Macarulla, et al.. (2024). TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS4188–TPS4188. 1 indexed citations
6.
Fan, Jia, Tanios Bekaii‐Saab, Luca Aldrighetti, et al.. (2024). A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.. Journal of Clinical Oncology. 42(16_suppl). TPS4199–TPS4199. 4 indexed citations
7.
8.
Okusaka, Takuji, Akio Saiura, Kazuaki Shimada, et al.. (2023). Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort. Journal of Gastroenterology. 58(12). 1261–1271. 5 indexed citations
9.
Shibuki, Taro, Mitsuhito Sasaki, Hiroshi Imaoka, et al.. (2023). Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Radiation Oncology. 18(1). 178–178. 1 indexed citations
10.
Llovet, Josep M., Amit G. Singal, Augusto Villanueva, et al.. (2022). Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research. 28(11). 2297–2305. 13 indexed citations
11.
Okusaka, Takuji, Masatoshi Kudo, Kenji Ikeda, et al.. (2022). Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma. Hepatology Research. 52(9). 784–793. 1 indexed citations
12.
Ikeda, Masafumi, Chigusa Morizane, Susumu Hijioka, et al.. (2020). Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology. 20(5). 944–950. 10 indexed citations
13.
Hashimoto, Yusuke, Izumi Ohno, Hideaki Takahashi, et al.. (2018). EUS-guided n-butyl-2-cyanoacrylate injection therapy for ruptured isolated left gastric artery pseudoaneurysm. Endoscopic Ultrasound. 8(1). 58–58. 5 indexed citations
14.
Saito, Kosuke, et al.. (2018). Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients. Cancer Chemotherapy and Pharmacology. 82(4). 677–684. 19 indexed citations
15.
16.
Ueno, Makoto, Masafumi Ikeda, Hiroshi Ishii, et al.. (2017). A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemotherapy and Pharmacology. 80(2). 307–315. 8 indexed citations
17.
Ikeda, Masafumi, Takuji Okusaka, Shuichi Mitsunaga, et al.. (2015). Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 22(6). 1385–1394. 141 indexed citations
18.
Suzuki, Shinya, Misaki Kobayashi, Hiroyuki Okuyama, et al.. (2013). Risk Factor of the Hand/foot Skin Reaction Induced by Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 39(5). 322–326. 1 indexed citations
19.
Ozaki, T., et al.. (2008). Operational Status of 20mN class Ion Engine Subsystem for ETS-VIII. 한국추진공학회 학술대회논문집. 511–518. 2 indexed citations
20.
Ikeda, Masafumi, Takuji Okusaka, Hideki Ueno, et al.. (2007). Hepatic Arterial Infusion Chemotherapy with Epirubicin in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis. Oncology. 72(3-4). 188–193. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tim Meyer Breakdown of academic impact, for papers by Robin Kate Kelley Breakdown of academic impact, for papers by Takuji Okusaka Breakdown of academic impact, for papers by Daniel H. Palmer Breakdown of academic impact, for papers by Valérie Boige Breakdown of academic impact, for papers by Junji Furuse Breakdown of academic impact, for papers by Ho Yeong Lim Breakdown of academic impact, for papers by Shukui Qin Breakdown of academic impact, for papers by Sasan Roayaie Breakdown of academic impact, for papers by Ronnie T. P. Poon
Rankless by CCL
2026